Palisade Bio (PALI) Revenue (2011 - 2023)
Palisade Bio (PALI) reported Revenue of $250000.0 for Q1 2023, up 9900.0% on a QoQ basis from $2500.0 in Q4 2020.
Palisade Bio (PALI) has 11 years of Revenue data on file, last reported at $250000.0 in Q1 2023.
- Quarterly Revenue changed N/A year-over-year to $250000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $250000.0 (changed N/A YoY) and the FY2023 annual result came in at $250000.0, changed N/A from the prior year.
- Revenue climbed to $250000.0 in Q1 2023 per PALI's latest filing, from $2500.0 in the prior quarter.
- Across five years, Revenue topped out at $250000.0 in Q1 2023 and bottomed at $2500.0 in Q1 2019.
- The 3-year median for Revenue is $2500.0 (2019), against an average of $30990.4.
- The widest annual swing landed in 2019, when Revenue sank 96.87%; it then surged 140.8% in 2020.
- Tracing PALI's Revenue over 3 years: stood at $2500.0 in 2019, then changed by 0.0% to $2500.0 in 2020, then soared by 9900.0% to $250000.0 in 2023.
- Per Business Quant, the three latest PALI Revenue figures stand at $250000.0 (Q1 2023), $2500.0 (Q4 2020), and $2500.0 (Q3 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 250,000.00 |
| Dec 31, 2020 | 2,500.00 |
| Sep 30, 2020 | 2,500.00 |
| Jun 30, 2020 | 2,500.00 |
| Mar 31, 2020 | 6,020.00 |
| Dec 31, 2019 | 2,500.00 |
| Sep 30, 2019 | 2,500.00 |
| Jun 30, 2019 | 7,894.00 |
| Mar 31, 2019 | 2,500.00 |
| Dec 31, 2018 | 2,500.00 |
| Sep 30, 2018 | 2,500.00 |
| Jun 30, 2018 | 252,500.00 |
| Mar 31, 2018 | 2,500.00 |
| Dec 31, 2017 | 252,500.00 |
| Sep 30, 2017 | 2,500.00 |
| Jun 30, 2017 | 2,500.00 |
| Mar 31, 2017 | 2,500.00 |
| Dec 31, 2016 | 8,746.00 |
| Sep 30, 2016 | 2,500.00 |
| Jun 30, 2016 | 2,500.00 |
| Mar 31, 2016 | 2,500.00 |
| Dec 31, 2015 | 2,500.00 |
| Sep 30, 2015 | 2,500.00 |
| Jun 30, 2015 | 2,500.00 |
| Mar 31, 2015 | 2,917.00 |
| Dec 31, 2014 | 4,666.00 |
| Sep 30, 2014 | 5,000.00 |
| Jun 30, 2014 | 5,000.00 |
| Mar 31, 2014 | 4,167.00 |
| Dec 31, 2013 | 2,500.00 |
| Sep 30, 2013 | 2,500.00 |
| Jun 30, 2013 | 2,500.00 |
| Mar 31, 2013 | 102,500.00 |
| Dec 31, 2012 | 2,500.00 |
| Sep 30, 2012 | 170,833.00 |
| Jun 30, 2012 | 78,125.00 |
| Mar 31, 2012 | 156,250.00 |
| Dec 31, 2011 | 287,208.00 |
| Sep 30, 2011 | 103,417.00 |